The platform will only allow for advertisements for stem cell therapy treatments that are approved by the FDA and will also allow gene and cell therapy ads for products that aren’t FDA approved if they are “exclusively educational or informational in nature”.
While there are 23 FDA approved stem cell treatments, many other treatments are unproven and potentially dangerous.
“Google’s continuing stem cell problem is emblematic of a serious, broader problem with unproven biomedical offerings the company needs to address,” said Paul Knoepfler, PhD, a professor at the UC Davis School of Medicine in Sacramento.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
